XML 76 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
ALLIANCES (AstraZeneca) (Details)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Sep. 30, 2015
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Alliances Statement [Line Items]                        
Number of agreements in alliance 3                 3    
Net product sales                   $ 19,258 $ 17,702 $ 14,045
Alliance revenues                   1,518 1,725 2,515
Total Revenues $ 5,449 $ 5,254 $ 5,144 $ 4,929 $ 5,243 $ 4,922 $ 4,871 $ 4,391   20,776 19,427 16,560
Royalties                   (557) (618) (293)
Transitional services                   (37) (238) (122)
Divestiture gain                   (161) (564) (194)
Deferred income - Cash flow                   (642) (64) 218
Divestiture and other proceeds                   651 1,317 697
AstraZeneca [Member]                        
Alliances Statement [Line Items]                        
Proceeds received at closing for sale of business                       2,700
Total contingent regulatory and sales based milestone payments                       1,400
Contingent approval milestones                       800
Total contingent sales based milestones                       600
Contingent payments related to transfer of certain assets and businesses                       225
Business sale total consideration received                       179
Contingent regulatory milestone consideration received                   100    
Net product sales                   6   14
Alliance revenues                   125 129 182
Total Revenues                   131 129 196
Other (income)/expense - Amortization of deferred income                     (113) (105)
Royalties                   (228) (227) (215)
Transitional services                   (12) (7) (12)
Divestiture gain                 $ 79 (126)   (82)
Deferred income - Cash flow                     19 34
Divestiture and other proceeds                   302 216 $ 374
Deferred income         $ 38           $ 38  
AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                        
Alliances Statement [Line Items]                        
Royalty rate sales threshold - Minimum 500                 500    
Royalty rate sales threshold - Maximum $ 500                 $ 500    
AstraZeneca [Member] | Amylin Related Products [Member]                        
Alliances Statement [Line Items]                        
Royalty rate on net sales                     2.00% 2.00%
Royalty rate on net sales - 2017                   5.00%    
Royalty rate on net sales - 2018                   10.00%    
Royalty rate on net sales - 2019                   12.00%    
Royalty rate on net sales - 2020                   12.00%    
Percentage of potential future royalties transferred                   70.00%    
CPPIB [Member]                        
Alliances Statement [Line Items]                        
Royalties                   $ 97 $ 134  
Maximum [Member] | AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                        
Alliances Statement [Line Items]                        
Royalty rate on net sales                     27.00% 35.00%
Royalty rate on net sales - 2017                   12.00%    
Royalty rate on net sales - 2018                   20.00%    
Royalty rate on net sales - 2019                   22.00%    
Royalty rate on net sales - 2020                   25.00%    
Royalty rate on net sales - future periods                   20.00%    
Maximum [Member] | AstraZeneca [Member] | Amylin Related Products [Member]                        
Alliances Statement [Line Items]                        
Royalty rate on net sales - future periods                   10.00%    
Maximum [Member] | Royalty Pharma [Member] | Onglyza and Farxiga Products [Member]                        
Alliances Statement [Line Items]                        
Percentage of potential future royalties transferred                   25.00%    
Minimum [Member] | AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                        
Alliances Statement [Line Items]                        
Royalty rate on net sales                     9.00% 7.00%
Royalty rate on net sales - 2017                   12.00%    
Royalty rate on net sales - 2018                   20.00%    
Royalty rate on net sales - 2019                   22.00%    
Royalty rate on net sales - 2020                   25.00%    
Royalty rate on net sales - future periods                   14.00%    
Minimum [Member] | AstraZeneca [Member] | Amylin Related Products [Member]                        
Alliances Statement [Line Items]                        
Royalty rate on net sales - future periods                   5.00%    
Minimum [Member] | Royalty Pharma [Member] | Onglyza and Farxiga Products [Member]                        
Alliances Statement [Line Items]                        
Percentage of potential future royalties transferred                   20.00%